Post-treatment changes in tumor microenvironment: Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging

Cancer Imaging

Volumn , Issue , 2008, Pages 235-248

  Jordan, Benedicte F ^a   Galons, Jean Philippe ^b   Gillies, Robert J ^b  

^a Laboratory of Biomedical Magnetic Resonance   (Belgium)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650639672     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012374212-4.50094-8     Document Type: Chapter

References (39)

1. Artemov D., Bhujwalla Z.M., Bulte J.W. Magnetic resonance imaging of cell surface receptors using targeted contrast agents. Curr. Pharm. Biotechnol. 2004, 5:485-494.
2. Bammer R. Basic principles of diffusion-weighted imaging. Eur. J. Radiol. 2003, 45:169-184.
3. Bhujwalla Z.M., Artemov D., Natarajan K., Solaiyappan M., Kollars P., Kristjansen P.E. Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin. Cancer Res. 2003, 9:355-362.
4. Brasch R.C., Li K.C., Husband J.E., Keogan M.T., Neeman M., Padhani A.R., Shames D., Turetschek K. In vivo monitoring of tumor angiogenesis with MR imaging. Acad. Radiol. 2000, 7:812-823.
5. Chinnaiyan A.M., Prasad U., Shankar S., Hamstra D.A., Shanaiah M., Chenevert T.L., Ross B.D., Rehemtulla A. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci. U.S.A 2000, 97:1754-1759.
6. Daldrup H., Shames D.M., Wendland M., Okuhata Y., Link T.M., Rosenau W., Lu Y., Brasch R.C. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR Am. J. Roentgenol. 1998, 171:941-949.
7. de Lussanet Q.G., Backes W.H., Griffioen A.W., Padhani A.R., Baeten C.I., van Baardwijk A., Lambin P., Beets G.L., van Engelshoven J.M., Beets-Tan R.G. Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63:1309-1315.
8. Dowlati A., Robertson K., Cooney M., Petros W.P., Stratford M., Jesberger J., Rafie N., Overmoyer B., Makkar V., Stambler B., Taylor A., Waas J., Lewin J.S., McCrae K.R., Remick S.C. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002, 62:3408-3416.
9. Dzik-Jurasz A., Domenig C., George M., Wolber J., Padhani A., Brown G., Doran S. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002, 360:307-308.
10. Evelhoch J., Garwood M., Vigneron D., Knopp M., Sullivan D., Menkens A., Clarke L., Liu G. Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report. Cancer Res. 2005, 65:7041-7044.
11. Galbraith S.M., Maxwell R.J., Lodge M.A., Tozer G.M., Wilson J., Taylor N.J., Stirling J.J., Sena L., Padhani A.R., Rustin G.J. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J. Clin. Oncol. 2003, 21:2831-2842.
12. Galons J.P., Altbach M.I., Paine-Murrieta G.D., Taylor C.W., Gillies R.J. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1999, 1:113-117.
13. Hayes C., Padhani A.R., Leach M.O. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed. 2002, 15:154-163.
14. Hein P.A., Kremser C., Judmaier W., Griebel J., Pfeiffer K.P., Kreczy A., Hug E.B., Lukas P., DeVries A.F. Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study. Eur. J. Radiol. 2003, 45:214-222.
15. Jayson G.C., Zweit J., Jackson A., Mulatero C., Julyan P., Ranson M., Broughton L., Wagstaff J., Hakannson L., Groenewegen G., Bailey J., Smith N., Hastings D., Lawrance J., Haroon H., Ward T., McGown A.T., Tang M., Levitt D., Marreaud S., Lehmann F.F., Herold M., Zwierzina H. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J. Natl. Cancer Inst. 2002, 94:1484-1493.
16. Jennings D., Hatton B.N., Guo J., Galons J.P., Trouard T.P., Raghunand N., Marshall J., Gillies R.J. Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia 2002, 4:255-262.
17. Jordan B.F., Runquist M., Raghunand N., Baker A., Williams R., Kirkpatrick L., Powis G., Gillies R.J. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 2005, 7:475-485.
18. Jordan B.F., Runquist M., Raghunand N., Gillies R.J., Tate W.R., Powis G., Baker A.F. The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging. Clin. Cancer Res. 2005, 11:529-536.
19. Kauppinen R.A. Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance imaging and proton spectroscopy. NMR Biomed. 2002, 15:6-17.
20. Knopp M.V., Giesel F.L., Marcos H., Tengg-Kobligk H., Choyke P. Dynamic contrast-enhanced magnetic resonance imaging in oncology. Top. Magn. Reson. Imaging 2001, 12:301-308.
21. Kremser C., Judmaier W., Hein P., Griebel J., Lukas P., de Vries A. Preliminary results on the influence of chemoradiation on apparent diffusion coefficients of primary rectal carcinoma measured by magnetic resonance imaging. Strahlenther. Onkol. 2003, 179:641-649.
22. Mardor Y., Pfeffer R., Spiegelmann R., Roth Y., Maier S.E., Nissim O., Berger R., Glicksman A., Baram J., Orenstein A., Cohen J.S., Tichler T. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J. Clin. Oncol. 2003, 21:1094-1100.
23. Mardor Y., Roth Y., Lidar Z., Jonas T., Pfeffer R., Maier S.E., Faibel M., Nass D., Hadani M., Orenstein A., Cohen J.S., Ram Z. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res. 2001, 61:4971-4973.
24. Mayr N.A., Yuh W.T., Arnholt J.C., Ehrhardt J.C., Sorosky J.I., Magnotta V.A., Berbaum K.S., Zhen W., Paulino A.C., Oberley L.W., Sood A.K., Buatti J.M. Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J. Magn. Reson. Imag. 2000, 12:1027-1033.
25. Moffat B.A., Hall D.E., Stojanovska J., McConville P.J., Moody J.B., Chenevert T.L., Rehemtulla A., Ross B.D. Diffusion imaging for evaluation of tumor therapies in preclinical animal models. MAGMA 2004, 17:249-259.
26. Morgan B., Thomas A.L., Drevs J., Hennig J., Buchert M., Jivan A., Horsfield M.A., Mross K., Ball H.A., Lee L., Mietlowski W., Fuxuis S., Unger C., O'Byrne K., Henry A., Cherryman G.R., Laurent D., Dugan M., Marme D., Steward W.P. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol. 2003, 21:3955-3964.
27. Norris D.G. The effects of microscopic tissue parameters on the diffusion weighted magnetic resonance imaging experiment. NMR Biomed. 2001, 14:77-93.
28. Padhani A.R., Husband J.E. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin. Radiol. 2001, 56:607-620.
29. Padhani A.R., Leach M.O. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom. Imaging 2005, 30:324-341.
30. Preda A., van Vliet M., Krestin G.P., Brasch R.C., van Dijke C.F. Magnetic resonance macromolecular agents for monitoring tumor microvessels and angiogenesis inhibition. Invest. Radiol. 2006, 41:325-331.
31. Rijpkema M., Kaanders J.H., Joosten F.B., van der Kogel A.J., Heerschap A. Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors. J. Magn. Reson. Imag. 2001, 14:457-463.
32. Ross B.D., Moffat B.A., Lawrence T.S., Mukherji S.K., Gebarski S.S., Quint D.J., Johnson T.D., Junck L., Robertson P.L., Murasko K.M., Dong Q., Meyer C.R., Bland P.H., McConville P., Geng H., Rehemtulla A., Chenevert T.L. Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol. Cancer Ther. 2003, 2:581-587.
33. Seifert M.H., Jakob P.M., Jellus V., Haase A., Hillenbrand C. High-resolution diffusion imaging using a radial turbo-spin-echo sequence: implementation, eddy current compensation, and self-navigation. J. Magn. Reson. 2000, 144:243-254.
34. Stejskal E.O., Tanner J.E. Use of spin echo in pulsed magnetic field gradient to study anistropic, restricted diffusion and flow. J. Chem. Phys. 1965, 43:3579-3603.
35. Theilmann R.J., Borders R., Trouard T.P., Xia G., Outwater E., Ranger-Moore J., Gillies R.J., Stopeck A. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 2004, 6:831-837.
36. Tofts P.S., Brix G., Buckley D.L., Evelhoch J.L., Henderson E., Knopp M.V., Larsson H.B., Lee T.Y., Mayr N.A., Parker G.J., Port R.E., Taylor J., Weisskoff R.M. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J. Magn. Reson. Imag. 1999, 10:223-232.
37. Trouard T.P., Theilmann R.J., Altbach M.J., Gmitro A.F. High-resolution diffusion imaging with DIFRAD-FSE (diffusion-weighted radial acquisition of data with fast spin-echo) MRI. Magn. Reson. Med. 1999, 42:11-18.
38. van der Woude H.J., Bloem J.L., Verstraete K.L., Taminiau A.H., Nooy M.A., Hogendoorn P.C. Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery. AJR Am. J. Roentgenol. 1995, 165:593-598.
39. Wedam S.B., Low J.A., Yang S.X., Chow C.K., Choyke P., Danforth D., Hewitt S.M., Berman A., Steinberg S.M., Liewehr D.J., Plehn J., Doshi A., Thomasson D., McCarthy N., Koeppen H., Sherman M., Zujewski J., Camphausen K., Chen H., Swain S.M. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 2006, 24:769-777.